PT  - JOURNAL ARTICLE
AU  - Joshua W.D. Tobin
AU  - Anna Crothers
AU  - Ti Eric Ma
AU  - Peter Mollee
AU  - Maher K. Gandhi
AU  - Paul Scuffham
AU  - Greg Hapgood
TI  - A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma
AID  - 10.1101/2021.03.24.21254220
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.24.21254220
4099  - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21254220.short
4100  - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21254220.full
AB  - Recent data suggests the use of radiotherapy alone (RT) in Early-Stage Follicular Lymphoma is declining. Cost-effectiveness analysis of treatments has not been performed. We constructed a partitioning model (15-year horizon) to compare RT, combined-modality therapy (CMT) and immunochemotherapy with rituximab maintenance (ICT+RM) from a PET-staged cohort from the Australian Lymphoma Alliance. Lifetime direct health care costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were calculated. AUD $75,000 was defined as the willingness-to-pay threshold (WTP). The direct healthcare costs were: RT $12,791, CMT $29,391 and ICT+RM $42,644. Compared with RT, CMT demonstrated minimal improvement in QALYs (+0.01) and an ICER well above the WTP threshold ($1,535,488). Compared with RT, ICT+RM demonstrated an improvement in QALYs (+0.41) with an ICER of $73,319. Modelling a 25% cost reduction with a rituximab biosimilar led to further ICER reductions with ICT+RM ($52,476). ICT+RM is cost-effective in early stage FL from the Australian taxpayer perspective.Competing Interest StatementJWDT: Honorarium Roche PM: Advisory Boards: Celgene, Janssen and Amgen, Pfizer. Trial support: Janssen. The remaining authors declare no competing financial interest. Funding source:Funding StatementThe study was supported by an educational grant from Gilead (MKG) and the Mater Foundation. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Metro South Human Research Ethics Committee HREC/17/QPAH/651All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request